Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- MREO
- Price
- 0.42
- Stock movement up
- +0.04 (11.78%)
- Company name
- Mereo BioPharma Group PLC ADR
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 66.15M
- Ent value
- 24.46M
- Price/Sales
- 42.29
- Price/Book
- 1.42
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -31.57%
- 1 year return (CAGR)
- -85.57%
- 3 year return (CAGR)
- -22.29%
- 5 year return (CAGR)
- -32.87%
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
MREO does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 42.29 |
| Price to Book | 1.42 |
| EV to Sales | 15.63 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 159.13M |
| EPS (TTM) | -0.26 |
| FCF per share (TTM) | -0.21 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.56M |
| Gross profit (TTM) | -175.50K |
| Operating income (TTM) | -46.85M |
| Net income (TTM) | -41.51M |
| EPS (TTM) | -0.26 |
| EPS (1y forward) | -0.02 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -11.22% |
| Operating margin (TTM) | -2994.99% |
| Profit margin (TTM) | -2653.50% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 48.70M |
| Net receivables | 0.00 |
| Total current assets | 52.41M |
| Goodwill | 0.00 |
| Intangible assets | 643.00K |
| Property, plant and equipment | 1.60M |
| Total assets | 53.60M |
| Accounts payable | 879.00K |
| Short/Current long term debt | 397.00K |
| Total current liabilities | 6.02M |
| Total liabilities | 7.00M |
| Shareholder's equity | 46.60M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -32.71M |
| Capital expenditures (TTM) | 320.38K |
| Free cash flow (TTM) | -33.03M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -89.08% |
| Return on Assets | -77.44% |
| Return on Invested Capital | -88.32% |
| Cash Return on Invested Capital | -70.28% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.37 |
| Daily high | 0.44 |
| Daily low | 0.35 |
| Daily Volume | 6.32M |
| All-time high | 5.92 |
| 1y analyst estimate | 2.67 |
| Beta | 0.26 |
| EPS (TTM) | -0.26 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 1 Apr 2026 |
Downside potential
Loading...
Downside potential data
| MREO | S&P500 | |
| Current price drop from All-time high | -92.98% | -1.82% |
| Highest price drop | -95.18% | -56.47% |
| Date of highest drop | 29 Dec 2025 | 9 Mar 2009 |
| Avg drop from high | -61.14% | -10.84% |
| Avg time to new high | 857 days | 12 days |
| Max time to new high | 1713 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
66.15M
Marketcap category
Small-cap
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Employees
36
Investor relations
-
SEC filings
CEO
Denise Vera Pollard-Knight
Country
USA
City
London
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page